Japanese Drug Wholesaler Mediceo Paltac Holdings To Merge With Alfresa
This article was originally published in PharmAsia News
Major Japanese drug wholesalers Mediceo Paltac Holdings is in negotiations with Alfresa Holdings about a merger deal. The new company would have a 45 percent market share in prescription drug wholesale and even higher shares in over-the-counter drugs, as both Palatac KS and Alfresa subsidiary CS Yakuhin are major players in the OTC distribution business. Such high market shares could be a potential problem for antitrust clearance. (Click here for more - Japanese language
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.